Chronic myelogenous leukemia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 15: Line 15:


CML is more common in males than in females with male-to-female ratio varying between 1.2 and 1.7 in different studies [8, 20, 27]. The gender difference in incidence is less prominent in younger age groups.PMID:25814090
CML is more common in males than in females with male-to-female ratio varying between 1.2 and 1.7 in different studies [8, 20, 27]. The gender difference in incidence is less prominent in younger age groups.PMID:25814090
Chronic myelogenous leukemia accounts for 15% of adult leukemias, has an incidence of 1 to 2 cases per 100000 population, and has a male-to-female ratio of 1.3 to 1. Incidence increases with age. The median age at presentation is 45 to 55 years, although some series report a median age of up to 67 years (4, 5). This is important when therapeutic options are being considered. Stem-cell transplantation is associated with a high procedure-related mortality rate, and interferona therapy produces a higher incidence of neurotoxicity and other side effects in older patients. It also emphasizes the need to continue investigating better strategies for patients who may not benefit as much as younger patients from recent treatment discoveries.
PMID:
: 10428738


==Epidemiology==
==Epidemiology==

Revision as of 13:50, 13 May 2018

Chronic myelogenous leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic myelogenous leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic myelogenous leukemia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic myelogenous leukemia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic myelogenous leukemia epidemiology and demographics

CDC on Chronic myelogenous leukemia epidemiology and demographics

Chronic myelogenous leukemia epidemiology and demographics in the news

Blogs on Chronic myelogenous leukemia epidemiology and demographics

Directions to Hospitals Treating Chronic myelogenous leukemia

Risk calculators and risk factors for Chronic myelogenous leukemia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1–2 cases per 100,000 adults, and accounts for 15%

of newly diagnosed cases of leukemia in adults. PMID:24729196

Its incidence is 2 per 100 000/year. The peak age for the disease is 50 to 55.PMID:20221270

Published data on the annual incidence of CML varies from as low as 0.4/100,000 persons in some non-Western countries to 1.75/100,000 in the USA [7, 8, 9, 15, 16, 17, 18, 19]. As the incidence of CML increases by age, some of these variations are due to significant differences in the age distributions of the investigated populations (e.g. Western vs several non-Western countries). However, also figures on age-adjusted incidence vary considerably (0.7–1.8/100,000) between different studies.

The incidence in CML increases by age, at least up to 75–80 years (Fig. 1). In Europe, the median age at diagnosis of CML, as estimated from population-based registries, is 57–60 years (Table 1) [9, 20]. Importantly, this is about 10 years above the median age typically seen in clinical trials [19]. In children, CML is a very rare disease with an incidence of 0.6–1.2 million children/year [26].

CML is more common in males than in females with male-to-female ratio varying between 1.2 and 1.7 in different studies [8, 20, 27]. The gender difference in incidence is less prominent in younger age groups.PMID:25814090

Chronic myelogenous leukemia accounts for 15% of adult leukemias, has an incidence of 1 to 2 cases per 100000 population, and has a male-to-female ratio of 1.3 to 1. Incidence increases with age. The median age at presentation is 45 to 55 years, although some series report a median age of up to 67 years (4, 5). This is important when therapeutic options are being considered. Stem-cell transplantation is associated with a high procedure-related mortality rate, and interferona therapy produces a higher incidence of neurotoxicity and other side effects in older patients. It also emphasizes the need to continue investigating better strategies for patients who may not benefit as much as younger patients from recent treatment discoveries.

PMID:

10428738

Epidemiology

Incidence

Age

Gender

References

  1. 1.0 1.1 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.


Template:WikiDoc Sources